Shockwave Medical

Shockwave Medical, Inc. operates as a medical device company, which focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease, C2 catheters for treating coronary artery disease, and S4 catheters or treating below-the-knee peripheral artery disease. The company was founded by Daniel Hawkins, John M. Adams, and Todd J. Brinton in 2009 and is headquartered in Santa Clara, CA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

ShockWave Medical reports robust revenue growth and strategic expansion plans

ShockWave Medical's strong performance in Q4 and full year 2022 underscores its growth trajectory and market acceptance.
The company's strategic initiatives, including product approvals, acquisitions, and revenue outlook, position it for continued success in 2023.
While facing challenges in operational transitions and tax strategies, ShockWave Medical remains focused on leveraging opportunities for growth and market expansion.

Shockwave Medical reports stellar Q1 results and eyes global expansion

Shockwave Medical delivered robust Q1 2023 results, showcasing significant revenue growth and strong international performance.
The company's focus on market expansion, new product launches, and strategic acquisitions underpin its confidence in sustained growth.
While facing challenges such as staffing shortages and margin pressures, Shockwave Medical remains optimistic about its future prospects and market opportunities.
Continued investments in innovation, market expansion, and talent acquisition position the company well for future success and revenue growth.

Shockwave Medical reports robust Q2 earnings, eyes international growth

Shockwave Medical's strong financial performance in Q2 2023 reflects revenue growth, profitability, and operational efficiency.
Strategic investments, focus on market expansion, and upcoming product launches position the company for future success and revenue growth.
While facing challenges in product development and market uncertainties, Shockwave has opportunities for growth in international markets and product differentiation.

Shockwave Medical reports robust Q3 earnings and eyes global expansion

Shockwave Medical's strong Q3 performance, international growth, and promising product pipeline position the company for long-term success. Despite challenges in the U.S. peripheral business, the company remains confident in its evidence-backed interventions and overall growth potential. Strategic initiatives to address prior authorization issues and expand market presence underscore a proactive approach to sustaining growth.

Shockwave Medical reports record revenue and strategic growth initiatives

Shockwave Medical delivered strong financial performance in Q4 2023, with record revenue and profitability, driven by growth in key business segments and international markets.
The company's strategic focus on evidence-based market penetration, new product launches, and global expansion positions it for continued growth and market leadership.
Despite challenges in clinical evidence generation and reimbursement complexities, SWAV's proactive approach and financial strength offer resilience and growth opportunities.
SWAV's confidence in achieving milestones, expanding into new markets, and driving revenue growth through innovative products underscore a promising outlook for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shockwave Medical is developing the Lithoplasty™ family of balloon dilatation catheters that incorporate tiny lithotripsy electrodes designed to increase the compliance of rigid vascular and valvular lesions prior to low-pressure dilation, thereby limiting injury to healthy tissue and overcoming significant limitations of current revascularization technologies. The technology is built on traditional balloon catheter platforms rendering it inherently familiar and easy to use for cardiologists, interventional radiologists and vascular surgeons alike. In peripheral vessels, Lithoplasty™ could enable more effective angioplasty, less frequent bailout stent usage and enhanced lesion preparation prior to the use of drug eluting balloons (DEB) or bio-absorbable vascular scaffolds (BVS). In coronary vessels it could facilitate stent delivery and enhance vessel preparation prior to stent or BVS placement. Finally, in aortic valves the technology could vastly improve native tissue preparation prior to trans-catheter aortic valve replacement (TAVR) and valvuloplasty for those patients not suitable for TAVR.

Johnson & Johnson

Johnson & Johnson will pay $13.1 billion, or $335 a share, for Shockwave Medical, which has soared in 2024 in part on takeover speculation.

Johnson & Johnson To Buy Shockwave Medical For $13.1 Billion

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Shockwave Medical, Inc. (NASDAQ: SWAV) to Johnson & Johnson for $335.00 per share in cash is fair to Shockwave shareholders. Halper Sadeh encourages Shockwave shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether.

SWAV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Shockwave Medical, Inc. Is Fair to Shareholders

Shockwave Medical Inc (NASDAQ: SWAV) is in the green today after Johnson & Johnson (NYSE: JNJ) said it will buy the medical device maker for $12.5 billion. Shockwave Medical stock priced at a premium The all-cash agreement values each share of Shockwave Medical at $335 – a 5.0% premium on their previous close.

Johnson & Johnson to buy Shockwave Medical for $12.5 billion

Johnson & Johnson is buying the medical-devices maker for a total enterprise value of about $13.1 billion.

Johnson & Johnson to Buy Shockwave Medical. It's a Cardio Health Play.

Johnson & Johnson JNJ, -1.14% has agreed to acquire Shockwave Medical Inc. SWAV, -0.23% in an all-cash deal with an enterprise value of about $13 billion, the companies said Friday. J&J will pay $335 a share in cash, equal to a 4.7% premium over Shockwave's closing price Thursday at $319.99.

Johnson & Johnson to acquire Shockwave Medical in $13.1 billion deal

Johnson & Johnson will buy medical device maker Shockwave Medical for about $12.5 billion, the companies said on Friday, helping the healthcare conglomerate boost its portfolio of medical devices.

Johnson & Johnson to buy Shockwave Medical for $12.5 bln

NEW BRUNSWICK, N.J. & SANTA CLARA, Calif.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired. The transaction was approved by both companies' boards of directors. The a.

Johnson & Johnson to Acquire Shockwave Medical

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Reasons to Add ShockWave Medical (SWAV) to Your Portfolio Now

A report surfaced that Johnson & Johnson was in talks to acquire Shockwave, though neither company has confirmed the rumors. An analyst initiated coverage on the stock.

Why Shockwave Medical Stock Rallied as Much as 18% Higher This Week

Shockwave Medical's (SWAV) shares gain as rumors about its potential acquisition by an industry giant get media attention.

Shockwave Medical (SWAV) Up on Potential Acquisition Rumors

Shockwave Medical shares are trading more than 3% higher in Wednesday's session, having soared more than 10% since it was announced Johnson & Johnson (NYSE:JNJ) was considering buying it. The maker of medical devices to treat heart diseases was reported to be an acquisition target for the healthcare giant on Tuesday by the Wall Street Journal.

Shockwave Medical rallies as J&J mulls purchase

Shares of medical-device maker Shockwave Medical Inc. rose Tuesday following a report that Johnson & Johnson was in talks to acquire the company.

Shockwave Medical shares rise on report of acquisition talks with Johnson & Johnson

The California-based maker of medical devices that treat cardiovascular diseases has a market value of nearly $12 billion.

Johnson & Johnson Considers Deal for Shockwave Medical

Johnson & Johnson is in talks to buy medical device maker Shockwave Medical , the Wall Street Journal reported on Tuesday.

Johnson & Johnson considers deal to buy Shockwave Medical, WSJ reports

SANTA CLARA, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that the company will be participating in the 23rd Annual Needham Virtual Healthcare Conference, which is being held virtually from Monday, April 8 to Thursday, April 11, 2024.

Shockwave Medical to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Artivion

DexCom

Edwards Lifesciences

Transmedics Group Inc

We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.

Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024

Shockwave Medical specializes in developing and commercializing medical devices using IVL technology for treating calcified plaque in vascular and heart valve diseases. The company has achieved milestones such as obtaining reimbursement codes for coronary IVL procedures and EU MDR certification, strengthening its market position. SWAV remains well-positioned for future growth and opportunistic M&A transactions.

Why Shockwave Medical Stands Out In The Medical Device Sector

Does Shockwave Medical (SWAV) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Shockwave Medical (SWAV) a Strong Momentum Stock: Buy Now?

General Motors

Celsius Holdings

Lennar

Weatherford International PLC

Turnaround play General Motors and hot energy drink maker Celsius Holdings lead this weekend's watchlist.

General Motors, Celsius Lead Five Non-AI Stocks Near Buy Points

Shockwave Medical's (SWAV) fourth-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.

Shockwave Medical (SWAV) Q4 Earnings Beat, Revenues Rise Y/Y

Shockwave Medical, Inc. (SWAV) Q4 2023 Earnings Call Transcript

Shockwave Medical (SWAV) came out with quarterly earnings of $1.16 per share, beating the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $3.71 per share a year ago.

Shockwave Medical (SWAV) Surpasses Q4 Earnings and Revenue Estimates

SANTA CLARA, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months and full year ended December 31, 2023.

Shockwave Medical Reports Fourth Quarter and Full Year 2023 Financial Results

SANTA CLARA, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today the appointment of Renee Gaeta as Chief Financial Officer (CFO), effective February 5, 2024. Renee succeeds Dan Puckett, CFO at Shockwave since 2016, who previously announced his decision to retire.

Shockwave Medical Appoints Renee Gaeta as Chief Financial Officer

Shockwave Medical (SWAV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

News for Shockwave Medical Stock (SWAV)